Investigational Drug Information for BRL-15,572
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug BRL-15,572?
BRL-15,572 is an investigational drug.
There have been 6 clinical trials for BRL-15,572.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2000.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Leukemia. The leading clinical trial sponsors are GlaxoSmithKline, Community Based Medical College, Bangladesh, and Dhaka Medical College.
Summary for BRL-15,572
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 47 |
| WIPO Patent Applications | 21 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2000-04-01) |
| Vendors | 19 |
Recent Clinical Trials for BRL-15,572
| Title | Sponsor | Phase |
|---|---|---|
| Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms | Chang Gung Memorial Hospital | N/A |
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | Celgene | Phase 1/Phase 2 |
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | Mundipharma Research GmbH & Co KG | Phase 1/Phase 2 |
Clinical Trial Summary for BRL-15,572
Top disease conditions for BRL-15,572
Top clinical trial sponsors for BRL-15,572
US Patents for BRL-15,572
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
